FindTrial
Sign In

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (OBT) in Highly Treatment Experienced HIV-1 Infected Patients With Limited to No Treatment Options

Status
APPROVED_FOR_MARKETING
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT00377065
Enrollment
Unknown
Registered
2006-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2016-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections

Brief summary

This is a treatment use study to provide early access to MK0518 for the treatment of HIV-1 infection in patients who have limited or no treatment options due to virological failure, resistance, or intolerance to multiple antiretroviral regimens. Enrollment in this study is patient driven. Investigators are not proactively assigned. There is no target sample size and duration of the study is indefinite. For information on how to enroll in the study, see link below.

Interventions

DRUGraltegravir

raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks

Sponsors

Merck Sharp & Dohme LLC
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* HIV positive patients who have limited or no treatment options and have documented resistance

Exclusion criteria

* Patient has previously been on MK0518 therapy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026